Bulgarian Journal of Psychiatry, 2024; 9(1):27-35

The effect of topiramate on weight loss and metabolic syndrome in obese hospitalized patients with schizophrenia and schizoaffective disorder: a double-blind randomized controlled trial

Hamid Reza Kamravan1, Shakiba Gholamzad2, Mohammad Reza Khodaie Ardakani1, Gita Sadighi1

1University of Social Welfare and Rehabilitation Sciences – Tehran, Iran 2Iran University of Medical Sciences – Tehran, Iran

 Abstract. Background: An psycho c use increases the risk of weight gain and metabolic complications. We aimed to investigate the effect of topiramate on weight loss and metabolic complications. MethodsIn this 12-week double-blind clinical trial, 66 patients with schizophrenia and schizoaffective diagnosis were divided into equal intervention (an psycho c + topiramate) and control (an psycho c + placebo) groups. Results: Topiramate resulted in a weight loss of 2.65 kg a er 12 weeks and significantly decreased fas ng blood sugar (FBS) levels (p < 0.0001). Conclusion: Topiramate 100 mg/day in patients with schizophrenia and schizoaffective disorder treated with an psycho cs had a significant effect on weight loss and reduction of Body mass index (BMI) and FBS.

Keywords: topiramate, weight loss, metabolic syndrome, schizophrenia

Full text here.